PATENT USSN: 10/597,034 Atty Dckt No.: 034205.003

AMENDMENT

IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently amended) An <u>isolated</u> amino acid sequence comprising <u>a fragment of SEQ ID</u>

NO:4 and further comprising a diabetogenic epitope defined by EEQLRELRRQ (SEQ ID NO:1),

and wherein the isolated amino acid sequence is not SEQ ID NO:4.

2. (Canceled)

3. (Previously presented) The isolated amino acid sequence of claim 1, wherein the diabetogenic

epitope comprises part of a larger peptide or protein that does not occur naturally in nature.

4. (Previously presented) The isolated amino acid sequence of claim 1, wherein said amino acid

sequence is attached to a carrier protein, non-carrier protein, macromolecule or support.

5. (Previously presented) The isolated amino acid sequence of claim 4, wherein said amino acid

sequence is attached to a support, said support comprising a bead, plate, dish, cover slip, slide,

multiwell assay plate, or bio-assay chip.

6-20. (Canceled)

21. (Previously presented) A kit comprising one or more of the amino acid sequences according

to claim 1.

22-23. (Canceled)

24. (Original) The kit of claim 21, further comprising one or more beads, plates, dishes,

coverslips, slides, multi-well assay plates, bioassay chips, which may be attached or unattached

2

PATENT USSN: 10/597,034

Atty Dckt No.: 034205.003

to the diabetogenic epitope, protein or peptide comprising the diabetogenic epitope, nucleotide

sequence encoding the diabetogenic epitope, sequence complementary thereto, or fragment

thereof.

25. (Original) The kit of claim 21, further comprising one or more primary antibodies capable of

binding to the diabetogenic epitope, or protein comprising the diabetogenic epitope, one or more

secondary antibodies that are capable of binding to the primary antibody, solutions, reagents,

enzymes, or a combination thereof.

26-36. (Canceled)

3